Trial Profile
Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry (Phase 5, Protocol No. P07981 [Also Known as MK 8616-064])
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Glycopyrrolate; Neostigmine
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 26 Sep 2014 New trial record